Products/Services Used | Details | Operation |
---|---|---|
Recombinant Antibody Expression> | … In cases where a paired, Day 29 sample was available with sufficient viable cells for further sorting, a fourth tube was tested, which included a recombinant FITCconjugated mAb against CD179a2 (produced by GenScript, Piscataway, NJ, with FITC-conjugation per the … | Get A Quote |
Immunotherapies directed against B-cell surface markers have been a common developmental strategy to treat B-cell malignancies. The IgH surrogate light chain (SLC), comprised of the VpreB1 (CD179a) and Lamda5 (CD179b) subunits is expressed on pro- and pre-B cells where it governs preBCR-mediated autonomous survival signaling. We hypothesized that the pre-BCR might merit the development of targeted immunotherapies to decouple "autonomous" signaling in B-lineage acute lymphoblastic leukemia (B-ALL). We used the COG minimal residual disease (MRD) flow panel to assess pre-BCR expression in 36 primary patient samples accrued to COG standard and high-risk B-ALL studies through AALL03B1. We also assessed CD179a expres... More